Instrument Inactif

Communiqués Celsus Therapeutics PLC (ADR) Nasdaq

Actions

US15119A2024

Produits pharmaceutiques

Communiqués

08/09	Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums	AQ
27/08	Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference	AQ
18/08	Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy	AQ
13/08	Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform	AQ
04/08	Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation	AQ
22/07	Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity	AQ
21/07	Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics	AQ
07/07	Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board	AQ
29/06	Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones	AQ
05/06	Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026	AQ
04/06	Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026	AQ
29/05	Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor What This Means Segment Following ASCO Abstract Acceptance	AQ
28/05	Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance	AQ
21/05	Akari Therapeutics : Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models	PU
06/04	Akari Therapeutics : Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing	PU
18/03	Akari Therapeutics : Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026	PU
10/11	Akari Therapeutics : Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors	PU
06/06/25	Akari Therapeutics : 2024 IFRS Report	PU
15/11/24	Akari Therapeutics : Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio Secures $3.2m in PIPE Financing $50m Term Sheet Obtained for Available Financing under Equity Line of Credit Form 8 K	PU
08/11/24	Akari Therapeutics : Announces Shareholder Approval in Connection WithPeak Bio Inc. Merger Form 8 K	PU
05/06/24	Akari Therapeutics : 2023 Annual Report	PU
16/05/24	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights	AQ
01/05/24	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics	AQ
01/05/24	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity	AQ
16/04/24	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography Data at ARVO 2024	AQ